-+ 0.00%
-+ 0.00%
-+ 0.00%

Relmada Therapeutics Names Jørn Skibsted Jakobsen Chief Development Officer for Urology and Uro-Oncology

PUBT·11/16/2026 07:04:43
Relmada Therapeutics Names Jørn Skibsted Jakobsen Chief Development Officer for Urology and Uro-Oncology
  • Relmada Therapeutics appointed Jørn Skibsted Jakobsen chief development officer, urology and uro-oncology.
  • Jakobsen will lead clinical development across the pipeline, including the planned Phase 3 SPECTRUM program for NDV-01.
  • A board-certified urologist, Jakobsen led ADSTILADRIN’s pivotal clinical development program during his nine-year tenure at Ferring Pharmaceuticals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160200PRIMZONEFULLFEED9877744) on November 16, 2026, and is solely responsible for the information contained therein.